A Study of RX-10045 in the Treatment of Dry Eye Disease
- First Posted Date
- 2012-08-30
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- C.T. Development America, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01675570
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis
Phase 2
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: Vehicle for RX-10045 arm
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- C.T. Development America, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01639846
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
Phase 3
Completed
- Conditions
- Amyloidosis
- Interventions
- Drug: PlaceboDrug: KIACTA (eprodisate disodium)
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- C.T. Development America, Inc.
- Target Recruit Count
- 261
- Registration Number
- NCT01215747
- Locations
- 🇫🇷
Hôpital Henri Mondor, Creteil, France
🇹🇳Hôpital Charles Nicolle, Tunis, Tunisia
🇫🇷Hôpital Claude Huriez, Lille, France
© Copyright 2025. All Rights Reserved by MedPath